Long-acting PEGylated growth hormone in children with idiopathic short stature.

European journal of endocrinology（2022）

引用 2|浏览13

暂无评分

摘要

Fifty-two-week treatment with PEG-rhGH 0.1 or 0.2 mg/kg/week achieved significant improvement in HT-SDS and other growth-related variables, including HV, IGF-1 SDS, and IGF-1/IGFBP-3 ratio, in a dose-dependent manner. Both doses were well tolerated with similar safety profiles.

查看译文

关键词

growth hormone,long-acting

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要